115 related articles for article (PubMed ID: 38863355)
1. Are sodium-glucose co-transporter-2 inhibitors associated with improved outcomes in diabetic patients admitted to intensive care units with septic shock?
Ashcherkin N; Abdalla AA; Gupta S; Bhatt S; Yee CI; Cartin-Ceba R
Acute Crit Care; 2024 May; 39(2):251-256. PubMed ID: 38863355
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose cotransporter-2 inhibitor in risk of sepsis/septic shock among patients with type 2 diabetes mellitus-a retrospective analysis of nationwide medical claims data.
Hu WS; Lin CL
Naunyn Schmiedebergs Arch Pharmacol; 2024 Mar; 397(3):1623-1631. PubMed ID: 37698621
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study.
Jang J; Park S; Kim S; Kim SH; Oh YS; Sa YK; Hwang Y; Jang SW; Ihm SH; Choi Y
Eur J Prev Cardiol; 2024 Feb; 31(3):320-329. PubMed ID: 37798123
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
Lee S; Zhou J; Leung KSK; Wai AKC; Jeevaratnam K; King E; Liu T; Wong WT; Chang C; Wong ICK; Cheung BMY; Tse G; Zhang Q
Cardiovasc Drugs Ther; 2023 Jun; 37(3):561-569. PubMed ID: 35142921
[TBL] [Abstract][Full Text] [Related]
5. Postcardiac Surgery Euglycemic Diabetic Ketoacidosis in Patients on Sodium-Glucose Cotransporter 2 Inhibitors.
Auerbach JS; Gershengorn HB; Aljure OD; Lamelas J; Patel SS; Ferreira TD; Gonzalez LA; Cabrera JL
J Cardiothorac Vasc Anesth; 2023 Jun; 37(6):956-963. PubMed ID: 36872114
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.
Kanie T; Mizuno A; Takaoka Y; Suzuki T; Yoneoka D; Nishikawa Y; Tam WWS; Morze J; Rynkiewicz A; Xin Y; Wu O; Providencia R; Kwong JS
Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013650. PubMed ID: 34693515
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium-glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors.
Lee HF; Chan YH; Chuang C; Li PR; Yeh YH; Hsiao FC; Peng JR; See LC
Eur Heart J Cardiovasc Pharmacother; 2023 Jun; 9(4):301-310. PubMed ID: 36639127
[TBL] [Abstract][Full Text] [Related]
8. Intensive care unit versus high-dependency care unit admission on mortality in patients with septic shock: a retrospective cohort study using Japanese claims data.
Endo K; Mizuno K; Seki T; Joo WJ; Takeda C; Takeuchi M; Kawakami K
J Intensive Care; 2022 Jul; 10(1):35. PubMed ID: 35869538
[TBL] [Abstract][Full Text] [Related]
9. Clinical values of cerebral oxygen saturation monitoring in patients with septic shock.
Peng Q; Zhang L; Ai M; Huang L; Ai Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Nov; 46(11):1212-1219. PubMed ID: 34911855
[TBL] [Abstract][Full Text] [Related]
10. New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study.
Gao X; Zhang N; Lu L; Gao T; Chou OHI; Wong WT; Chang C; Wai AKC; Lip GYH; Zhang Q; Tse G; Liu T; Zhou J
Eur Heart J Cardiovasc Pharmacother; 2024 Feb; 10(2):103-117. PubMed ID: 37962962
[TBL] [Abstract][Full Text] [Related]
11. [Value of pulse indicator continuous cardiac output monitoring of cardiac function in septic shock patients: a prospective study].
Yi M; Yao G; Guo X
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2015 Jan; 27(1):22-7. PubMed ID: 25591432
[TBL] [Abstract][Full Text] [Related]
12. [Predictive value of glycemic variability within 6 hours on the short-term prognosis of patients with septic shock].
Sun C; Zhong B; Shen H; Zhu J
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Jan; 33(1):28-32. PubMed ID: 33565396
[TBL] [Abstract][Full Text] [Related]
13. Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study.
Chen TH; Li YR; Chen SW; Lin YS; Sun CC; Chen DY; Mao CT; Wu M; Chang CH; Chu PH; Wu VC
Cardiovasc Diabetol; 2020 Nov; 19(1):189. PubMed ID: 33167990
[TBL] [Abstract][Full Text] [Related]
14. [Clinical analysis of septic shock caused by acute upper and lower gastrointestinal perforation].
Wang H; Liu X; Bi H; Tang Y; Wang D
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Aug; 32(8):943-946. PubMed ID: 32912407
[TBL] [Abstract][Full Text] [Related]
15. Clinical Trajectory and Predictors of Intensive Care Unit Mortality Among Nonalcoholic Fatty Liver Disease Patients: A Retrospective Case-Control Study.
Janini E; Fteiha B; Ramlawi I; Mahamid M
J Clin Exp Hepatol; 2023; 13(2):218-224. PubMed ID: 36950493
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
17. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.
Riley DR; Essa H; Austin P; Preston F; Kargbo I; Ibarburu GH; Ghuman R; Cuthbertson DJ; Lip GYH; Alam U
Diabetes Obes Metab; 2023 Oct; 25(10):2897-2909. PubMed ID: 37385958
[TBL] [Abstract][Full Text] [Related]
18. Association of Continued Use of SGLT2 Inhibitors From the Ambulatory to Inpatient Setting With Hospital Outcomes in Patients With Diabetes: A Nationwide Cohort Study.
Singh LG; Ntelis S; Siddiqui T; Seliger SL; Sorkin JD; Spanakis EK
Diabetes Care; 2024 Jun; 47(6):933-940. PubMed ID: 38051789
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
Udell JA; Yuan Z; Rush T; Sicignano NM; Galitz M; Rosenthal N
Circulation; 2018 Apr; 137(14):1450-1459. PubMed ID: 29133607
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Inpatient Sodium-Glucose Co-Transporter-2 Inhibitor Use in Patients Hospitalized for Acute Heart Failure.
Yan CL; Erben A; Sancassani R
Am J Cardiol; 2024 Jan; 211():175-179. PubMed ID: 37944775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
